These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 18930025)

  • 1. Interaction of onconase with the human ribonuclease inhibitor protein.
    Turcotte RF; Raines RT
    Biochem Biophys Res Commun; 2008 Dec; 377(2):512-514. PubMed ID: 18930025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evasion of ribonuclease inhibitor as a determinant of ribonuclease cytotoxicity.
    Rutkoski TJ; Raines RT
    Curr Pharm Biotechnol; 2008 Jun; 9(3):185-9. PubMed ID: 18673284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disruption of shape-complementarity markers to create cytotoxic variants of ribonuclease A.
    Rutkoski TJ; Kurten EL; Mitchell JC; Raines RT
    J Mol Biol; 2005 Nov; 354(1):41-54. PubMed ID: 16188273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the N terminus in RNase A homologues: differences in catalytic activity, ribonuclease inhibitor interaction and cytotoxicity.
    Boix E; Wu Y; Vasandani VM; Saxena SK; Ardelt W; Ladner J; Youle RJ
    J Mol Biol; 1996 Apr; 257(5):992-1007. PubMed ID: 8632481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of the C30/C75 disulfide bond to the biological properties of onconase.
    Torrent G; Benito A; Castro J; Ribó M; Vilanova M
    Biol Chem; 2008 Aug; 389(8):1127-36. PubMed ID: 18979636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The interdependence between catalytic activity, conformational stability, and cytotoxicity of onconase.
    Schulenburg C; Ardelt B; Ardelt W; Arnold U; Shogen K; Ulbrich-Hofmann R; Darzynkiewicz Z
    Cancer Biol Ther; 2007 Aug; 6(8):1233-9. PubMed ID: 17637563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural basis for catalysis by onconase.
    Lee JE; Bae E; Bingman CA; Phillips GN; Raines RT
    J Mol Biol; 2008 Jan; 375(1):165-77. PubMed ID: 18001769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of dynamic effects on the enzyme activity: X-ray structure and molecular dynamics of onconase mutants.
    Merlino A; Mazzarella L; Carannante A; Di Fiore A; Di Donato A; Notomista E; Sica F
    J Biol Chem; 2005 May; 280(18):17953-60. PubMed ID: 15728177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzymatic and structural characterisation of amphinase, a novel cytotoxic ribonuclease from Rana pipiens oocytes.
    Singh UP; Ardelt W; Saxena SK; Holloway DE; Vidunas E; Lee HS; Saxena A; Shogen K; Acharya KR
    J Mol Biol; 2007 Aug; 371(1):93-111. PubMed ID: 17560606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ribonuclease inhibitor as an intracellular sentry.
    Haigis MC; Kurten EL; Raines RT
    Nucleic Acids Res; 2003 Feb; 31(3):1024-32. PubMed ID: 12560499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crystal structure of RNase A tandem enzymes and their interaction with the cytosolic ribonuclease inhibitor.
    Arnold U; Leich F; Neumann P; Lilie H; Ulbrich-Hofmann R
    FEBS J; 2011 Jan; 278(2):331-40. PubMed ID: 21134128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crystal structure of Onconase at 1.1 Å resolution--insights into substrate binding and collective motion.
    Holloway DE; Singh UP; Shogen K; Acharya KR
    FEBS J; 2011 Nov; 278(21):4136-49. PubMed ID: 21895975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive comparison of the cytotoxic activities of onconase and bovine seminal ribonuclease.
    Matousek J; Soucek J; Slavík T; Tománek M; Lee JE; Raines RT
    Comp Biochem Physiol C Toxicol Pharmacol; 2003 Dec; 136(4):343-56. PubMed ID: 15012906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Onconase cytotoxicity relies on the distribution of its positive charge.
    Turcotte RF; Lavis LD; Raines RT
    FEBS J; 2009 Jul; 276(14):3846-57. PubMed ID: 19523116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of active-site residues to the function of onconase, a ribonuclease with antitumoral activity.
    Lee JE; Raines RT
    Biochemistry; 2003 Oct; 42(39):11443-50. PubMed ID: 14516195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bactericidal activity engineered on human pancreatic ribonuclease and onconase.
    Torrent G; Ribó M; Benito A; Vilanova M
    Mol Pharm; 2009; 6(2):531-42. PubMed ID: 19718804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycosylation of onconase increases its conformational stability and toxicity for cancer cells.
    Kim BM; Kim H; Raines RT; Lee Y
    Biochem Biophys Res Commun; 2004 Mar; 315(4):976-83. PubMed ID: 14985108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single amino acid substitutions at the N-terminus of a recombinant cytotoxic ribonuclease markedly influence biochemical and biological properties.
    Newton DL; Boque L; Wlodawer A; Huang CY; Rybak SM
    Biochemistry; 1998 Apr; 37(15):5173-83. PubMed ID: 9548748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Constitutive expression and anticancer potency of a novel immunotoxin onconase-DV3.
    Sun M; Tang H; Gao Y; Dai X; Yuan Y; Zhang C; Sun D
    Oncol Rep; 2016 Apr; 35(4):1987-94. PubMed ID: 26782924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dissimilarity in the reductive unfolding pathways of two ribonuclease homologues.
    Narayan M; Xu G; Ripoll DR; Zhai H; Breuker K; Wanjalla C; Leung HJ; Navon A; Welker E; McLafferty FW; Scheraga HA
    J Mol Biol; 2004 May; 338(4):795-809. PubMed ID: 15099746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.